Draft Medical Policies
BlueCross BlueShield of Tennessee

BlueCross BlueShield of Tennessee works to ensure that Medical Policies are developed in an open, collaborative manner with our providers. We invite you to submit comments during the development phase of our Medical Policies.

Medical policies are developed using an evidence-based evaluation process. The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and expert opinions from BCBST network specialists. We especially welcome comments that include this type of information. All Medical Policies are reviewed and approved by a panel of BCBST Medical Directors as well as board certified network physicians before final adoption by the company.

Tracking Number

Medical Policy Name

Beginning of Comment Period

End of Comment Period


Positron Emission Tomography (PET) for Oncologic Applications

06/03/16 07/03/16

Genetic Testing for Epilepsy

06/03/16 07/03/16

Intravenous Immune Globulin (IVIG) Therapy

06/10/16 07/10/16


06/10/16 07/10/16

Multi-gene Expression Assay for Predicting Recurrence in Colon Cancer

06/14/16 07/14/16


06/15/16 07/15/16
DMP0616-07 Noninvasive Techniques for Evaluation and Monitoring of Chronic Liver Diseases 06/17/16 07/17/16

Microwave Tumor Ablation

06/20/16 07/20/16

Radioembolization for Primary Tumors of the Liver and Metastatic Tumors to the Liver

06/20/16 07/20/16

Positron Emission Tomography (PET) for Miscellaneous Applications

06/22/16 07/22/16


Medical Policy Comments:

Please reference the policy name or tracking number in your comments.
To submit comments about the draft Medical Policies:
Click the “Medical Policy Comments” above or click here: Comments or Feedback.

Comments can also be mailed to:

BlueCross BlueShield of Tennessee
Medical Policy
1 Cameron Hill Circle
Chattanooga, TN 37402